T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Immunity

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 17441676PMCID PMC2935756
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

  2007cited by this paper
• In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope

  2006cited by this paper
• NY-ESO-1: review of an immunogenic tumor antigen.

  2006cited by this paper
• HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan

  2006cited by this paper
• Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

  2006cited by this paper
• Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5

  2006cited by this paper
• Distinct Structural TCR Repertoires in Naturally Occurring Versus Vaccine-Induced CD8+ T-Cell Responses to the Tumor-Specific Antigen NY-ESO-1

  2005cited by this paper
• Cancer/testis antigens, gametogenesis and cancer

  2005cited by this paper
• CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.

  2005cited by this paper
• Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions

  2005cited by this paper
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  2004cited by this paper
• The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.

  2004cited by this paper
• NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer

  2004cited by this paper
• The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level.

  2004cited by this paper
• NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors

  2004cited by this paper
• NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer

  2004cited by this paper
• NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors

  2004cited by this paper
• NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

  2003cited by this paper
• Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

  2003cited by this paper
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

  2003cited by this paper
• Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

  2003cited by this paper
• CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

  2002cited by this paper
• Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

  2002cited by this paper
• Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

  2001cited by this paper
• Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1

  2001cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

  2000cited by this paper
• Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma

  2000cited by this paper
• Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

  2000cited by this paper
• Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events

  1999cited by this paper
• Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.

  1999cited by this paper
• Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

  1998cited by this paper
• Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin.

  1998cited by this paper
• Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies

  1998cited by this paper
• A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

  1998cited by this paper
• A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.

  1998cited by this paper
• Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods.

  1997cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper
• Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene

  1994cited by this paper

• Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer

  2025cites this paper
• The paths toward immunotherapy of esophageal cancer: An overview of clinical trials.

  2025cites this paper
• Potential of Pullulan-Based Polymeric Nanoparticles for Improving Drug Physicochemical Properties and Effectiveness

  2024cites this paper
• Cholesterol-Bearing Polysaccharide-Based Nanogels for Development of Novel Immunotherapy and Regenerative Medicine

  2024cites this paper
• Investigating preparation and characterisation of diphtheria toxoid‐loaded on sodium alginate nanoparticles

  2022cites this paper
• Nanogels as target drug delivery systems in cancer therapy: A review of the last decade

  2022cites this paper
• Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

  2022cites this paper
• Recent Advances in the Biomedical Applications of Functionalized Nanogels

  2022cites this paper
• Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ

  2021cites this paper
• Design and Development of Hybrid Hydrogels for Biomedical Applications: Recent Trends in Anticancer Drug Delivery and Tissue Engineering

  2021cites this paper
• Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring

  2021cites this paper
• The Use of Nanobiotechnology in Immunology and Vaccination

  2021cites this paper
• Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

  2020cites this paper
• First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

  2020cites this paper
• PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.

  2020cites this paper
• Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody

  2020cites this paper
• Immunotherapy for esophageal cancer: a 2019 update.

  2020cites this paper
• New Developments in Medical Applications of Hybrid Hydrogels Containing Natural Polymers

  2020cites this paper
• Polysaccharide-Based Biomaterials for Protein Delivery

  2020cites this paper
• Structural and Functional Analysis of Pullulanase Type 1 (PulA) from Geobacillus thermopakistaniensis

  2020cites this paper
• Immunotherapy in gastroesophageal cancers: Current state and future directions

  2020cites this paper
• Recent developments in stimuli-responsive polymer nanogels for drug delivery and diagnostics: A Review.

  2020cites this paper
• Exopolysaccharide and biopolymer-derived films as tools for transdermal drug delivery.

  2020cites this paper
• Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy

  2019cites this paper
• Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

  2019cites this paper
• Hybrid Nanogels: Stealth and Biocompatible Structures for Drug Delivery Applications

  2019cites this paper
• Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.

  2019cites this paper
• Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy

  2019cites this paper
• Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers.

  2018cites this paper
• Structural effects and lymphocyte activation properties of self-assembled polysaccharide nanogels for effective antigen delivery

  2018cites this paper
• Saccharides, oligosaccharides, and polysaccharides nanoparticles for biomedical applications

  2018cites this paper
• Research progress of self-assembled nanogel and hybrid hydrogel systems based on pullulan derivatives

  2018cites this paper
• The evolving immunotherapeutic landscape in advanced oesophagogastric cancer

  2018cites this paper
• Nanogels as potential drug nanocarriers for CNS drug delivery.

  2018cites this paper
• Nanocellulose and Nanogels as Modern Drug Delivery Systems

  2017cites this paper
• Nanometric Biopolymer Devices for Oral Delivery of Macromolecules with Clinical Significance

  2017cites this paper
• Nanoparticles: nanoscale systems for medical applications

  2017cites this paper
• Expression and immunogenicity of NY-ESO-1 in colorectal cancer.

  2017cites this paper
• Harnessing Nanoparticles for Immunomodulation and Vaccines

  2017cites this paper
• Possible functions of CD169‐positive sinus macrophages in lymph nodes in anti‐tumor immune responses

  2017cites this paper
• NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC

  2017cites this paper
• Translational nanoparticle engineering for cancer vaccines

  2017cites this paper
• Melanoma: tumor microenvironment and new treatments

  2017cites this paper
• Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

  2017cites this paper
• Promising immunotherapies for esophageal cancer

  2017cites this paper
• Supramolecular polymeric biomaterials.

  2017cites this paper
• Lewis-Sumner syndrome associated with infliximab therapy for psoriasis*

  2017cites this paper
• Pivotal Role of Lymph Node Sinus Macrophages and Anti-Tumor Immune Responses in Patients with Malignant Tumors

  2017cites this paper
• Análise da expressão da proteína NY-ESO-1 no melanoma cutâneo

  2016cites this paper
• Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

  2016cites this paper
• Maturation of dendritic cells by pullulan promotes anti-cancer effect

  2016cites this paper
• Emerging immunotherapy for the treatment of esophageal cancer

  2016cites this paper
• Investigation into Self-Assembling Microcrystals as an alternative to polysaccharide-based conjugate vaccines

  2016cites this paper
• Immunological Evaluation of Biodegradable Particle Based Nanoparticles Encapsulating OMP Antigen as Potential Vaccine Candidate

  2016cites this paper
• Immunotherapy for Gastroesophageal Cancer

  2016cites this paper
• Inducible expression of cancer-testis antigens in human prostate cancer

  2016cites this paper
• Current advances in self-assembled nanogel delivery systems for immunotherapy.

  2015cites this paper
• Applications of Nanomaterials for Activation and Suppression of Immune Responses

  2015cites this paper
• Cholesterol Modified Self-Assemblies and Their Application to Nanomedicine.

  2015cites this paper
• Stimuli-responsive nanogel composites and their application in nanomedicine.

  2015cites this paper
• Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan

  2015cites this paper
• Nanocarrier‐Integrated Microspheres: Nanogel Tectonic Engineering for Advanced Drug‐Delivery Systems

  2015cites this paper
• Vaccine Nanocarriers: The Future Ahead

  2015cites this paper
• Nanogel-crosslinked nanoparticles increase the inhibitory effects of W9 synthetic peptide on bone loss in a murine bone resorption model

  2015cites this paper
• Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

  2015cites this paper
• Nanoparticle vaccines.

  2014cites this paper
• Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

  2014cites this paper
• Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.

  2014cites this paper
• Cancer/testis antigens: A prospective reagent as diagnostic and immunotherapeutic targets for squamous cell carcinoma of the head and neck

  2014cites this paper
• Development of nanogel engineering for new protein drug delivery system and medical applications

  2014cites this paper
• High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

  2014cites this paper
• NY‐ESO‐1 expression is tightly linked to TMPRSS2–ERG fusion in prostate cancer

  2014cites this paper
• Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen

  2014cites this paper
• Self-Assembled Polysaccharide Nanogels for Nasal Delivery of Biopharmaceuticals

  2014cites this paper
• NY-ESO-1 antibody as a novel tumour marker of gastric cancer

  2013cites this paper
• Polymeric nanogels as vaccine delivery systems.

  2013cites this paper
• Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

  2013cites this paper
• Nanogel bottom-up gel biomaterials for protein delivery: Photopolymerization of an acryloyl-modified polysaccharide nanogel macromonomer

  2013cites this paper
• Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients

  2013cites this paper
• Self-assembled pH-sensitive cholesteryl pullulan nanogel as a protein delivery vehicle.

  2013cites this paper
• Induction of CD8 T‐cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20‐mer NY‐ESO‐1f (NY‐ESO‐1 91‐110) peptide

  2013cites this paper
• Applications of nanotechnology for immunology

  2013cites this paper
• Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity

  2012cites this paper
• Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide.

  2012cites this paper
• Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination

  2012cites this paper
• Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

  2012cites this paper
• Cancer‐testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

  2012cites this paper
• Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

  2012cites this paper
• Trial watch

  2012cites this paper
• Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity

  2011cites this paper
• Therapeutic vaccines for gastrointestinal cancers.

  2011cites this paper
• Configuration and rearrangement of the human GAGE gene clusters.

  2011cites this paper
• Loss of Bloom syndrome protein causes destabilization of genomic architecture and is complemented by ectopic expression of Escherichia coli Recg in human cells

  2011cites this paper
• 新規がん抗原 GKAP1 の同定と口腔扁平上皮癌での発現解析

  2011cites this paper
• A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen

  2011cites this paper
• Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.

  2010cites this paper
• Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

  2010cites this paper
• Self-assembled Nanogel Engineering

  2010cites this paper
• Cancer–germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment

  2010cites this paper
• Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.

  2010cites this paper